SRXH SRx Health: Company Short-Term Debts

Public company logo of SRx Health Solutions Inc. (SRXH)

The growth of SRx Health Solutions Inc. (SRXH) is based on the demand for orphan drugs and the success of clinical trials. The level of short-term loans visualizes these cycles, and this metric equals 0.00. Business efficiency is supported by eco-logistics and packaging recycling, as well as the synergy between qualified pharmacists and patient care managers in Canada.

SRXH (SRx Health Solutions Inc.) Company Short-Term Debts history from 05/01/2025 to 10/31/2026

Metric breakdowns and analytics for SRx Health Solutions Inc (SRXH)

- stock price and consensus target price:
Stock Price SRx Health|SRXH - Consensus Target
- company stock capitalization data:
Market Capitalization SRx Health Solutions Inc.|SRXH - Company Buyout Price
- business book valuation details:
Book Value per Share SRx Health Solutions|SRXH - Book Capitalization|Market Value to Book Value Ratio srxhealth.com|SRXH - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital SRx Health Solutions Inc.|SRXH - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio SRx Health|SRXH - Company Aggregate Indebtedness|Debts to Book Capitalization SRx Health Solutions Inc.|SRXH - Long-Term Debt|Company Short-Term Debts SRx Health Solutions|Quick Liquidity Indicator srxhealth.com
- net income and valuation multiples indicators:
SRXH - Final Profit
Summary company analysis:srxhealth.com (SRXH)
Manufactured products of SRx Health Solutions Inc.

This indicator measures the volume of liabilities with a maturity of up to one year, reflecting the ability of SRx Health Solutions Inc. (SRXH) to service current debt without compromising operational activities. By analyzing total short-term liabilities, an investor assesses liquidity risk, which is exacerbated for the company by geopolitical instability and the disruption of supply chains limiting access to key pharmaceutical sales markets.

Main competitors

Vertex - Company Short-Term Debts|Alnylam Pharmaceuticals, Inc. (ALNY) - Company Current Liabilities|INSM: Company Short-Term Debts|UTHR - Short-Term Debt Volume|BMRN (BioMarin Pharmaceutical) - Company Short-Term Debts|Company Short-Term Debts bridgebio.com|Company Short-Term Debt BGM Group Ltd (BGM)|Company Short-Term Debt COGT (Cogent Biosciences Inc)|Company Short-Term Debts XERS (Xeris Biopharma Inc)|Short-Term Debt Volume Keros Corp (KROS)|ARCT: Company Current Liabilities|Current Liabilities ETON|KMDA: Company Short-Term Debts|Short-Term Debt Fulcrum Therapeutics Inc (FULC)|ABEO (Abeona Therapeutics, Inc.) - Company Short-Term Debts|Company Short-Term Indebtedness MREO (Mereo BioPharma Group PLC)|Company Current Liabilities PLX (Protalix BioTherapeutics)|PLRX (pliantrx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Applied Therapeutics APLT|RNTX (Rein Therapeutics Inc.) - Current Liabilities|Gelteq Limited Inc - Company Short-Term Debts|Company Short-Term Loans and Borrowings AYTU (Aytu BioPharma, Inc.)|CMMB: Company Short-Term Debts|Polyrizon (PLRZ) - Company Short-Term Debts|Company Short-Term Debt Aeterna Zentaris Inc|CYTH: Company Short-Term Loans and Borrowings|Company Short-Term Debt Inozyme Pharma, Inc. (INZY)|Company Current Liabilities Reneo Pharmaceuticals, Inc RPHM|Company Short-Term Debts CSCI (COSCIENS Biopharma Inc.)